KBC Group’s Nuvation Bio NUVB Stock Holding History

KBC Group’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$49K	Hold	8,699	–	–	﹤0.01%	1726
2026 Q2	$49K	Hold	8,699	–	–	﹤0.01%	1715
2026 Q1	$37K	Buy	+8,699	New	+$48.5K	﹤0.01%	1748

Other funds holding NUVB

Laurion Capital Management New York $6.21B AUM 32.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Essex Investment Management Boston, Massachusetts $675M AUM 61.81% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ACPLP

ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM

Mizuho Markets Americas New York $6.82B AUM 29.92% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return

KBC Group's NUVB Position: Q3 2026 in Review

KBC Group held its Nuvation Bio (NUVB) position steady in Q3 2026 at 8,699 shares worth $49K. The position accounts for ﹤0.01% of the portfolio, ranked #1726.

KBC Group first reported a position in NUVB in Q1 2026 and has held it in 3 quarters since. 93 funds tracked by Wall St. Rank hold NUVB as of Q3 2026.

KBC Group held 8,699 shares of Nuvation Bio worth $49K as of Q3 2026.
KBC Group left its Nuvation Bio share count unchanged in Q3 2026.
Nuvation Bio made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1726 holding.
KBC Group first reported a position in Nuvation Bio in Q1 2026 and has held it in 3 quarters since.
93 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.